NSCLC, FDA and Tagrisso
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of unresectable,
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.
FDA Approves Osimertinib in Stage III NSCLC
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.
FDA Expands Approval of Osimertinib in Lung Cancer
The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) following chemoradiotherapy, the agency announced Wednesday.
AstraZeneca gets FDA expanded approval for Tagrisso
AstraZeneca (NASDAQ:AZN) has received FDA approval for its drug Tagrisso for the treatment of patients with unresectable Stage 3 EGFR-mutant non-small cell lung cancer, or NSCLC. The agency approved Tagrisso,
Medscape1d
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
Business Wire2d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Tagrisso (osimertinib)​ for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) ...
pharmaphorum2d
AZ gets sought-after lung cancer approval for Tagrisso
AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a ...